Viking Therapeutics stock, VK2735

Viking Therapeutics stock: VK2735 data show BMI gains

Published on 11/17/2026 at 13:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Viking Therapeutics stock is tied to fresh VK2735 obesity data. A Phase 2 analysis found broad BMI-category and cardiometabolic improvements after 13 weeks.

Key takeaways from VK2735

  • The VENTURE analysis covered weekly subcutaneous treatment and changes in obesity severity after 13 weeks.
  • Participants who improved their BMI category also recorded better glucose, lipid, blood-pressure and waist measurements.
  • VANQUISH-1 and VANQUISH-2 are evaluating weekly VK2735 injections over 78 weeks, with completion expected in 2027.
Viking Therapeutics stock, VK2735, obesity drugs, clinical trials, biopharma, Illustration mit AI erstellt.

Viking Therapeutics announced new clinical data for its obesity candidate VK2735 on Nov. 15, with a Phase 2 analysis showing improvements in obesity severity and cardiometabolic markers. The company presented the findings at ObesityWeek 2026 in Washington, D.C., according to PR Newswire.

VK2735 data strengthen obesity case

The exploratory VENTURE analysis found that 74 percent of participants receiving weekly subcutaneous VK2735 improved by at least one body mass index category after 13 weeks, compared with 15 percent of placebo participants. None of the VK2735-treated participants moved into a higher BMI category.

The analysis included 124 treated participants. Among those who improved their BMI category, Viking reported reductions in waist circumference, fasting insulin and glucose, blood pressure, total cholesterol, triglycerides and LDL cholesterol. The company also cited earlier VENTURE results showing weight loss of up to 14.7 percent after 13 weeks and at least 10 percent weight loss for as many as 88 percent of treated patients, compared with 4 percent for placebo.

Phase 3 program moves toward 2027

Viking is developing VK2735 as a dual GLP-1 and GIP receptor agonist in injectable and oral formulations. The ongoing Phase 3 VANQUISH program includes VANQUISH-1 in adults with obesity and VANQUISH-2 in adults with obesity and type 2 diabetes. Both trials assess once-weekly injections over 78 weeks, with completion expected in 2027.

Viking Therapeutics stock traded at 24.40 euros on Lang & Schwarz at 13:35:33 CET on Tuesday, Nov. 17, 2026.

Viking Therapeutics at a glance

  • Company: Viking Therapeutics, Inc.
  • Ticker: VKTX
  • Primary exchange: Nasdaq
  • Lang & Schwarz quote: 24.40 euros at 13:35:33 CET on Nov. 17, 2026
  • Lead program: VK2735

The Nasdaq Composite provides the broader U.S. market setting for biotechnology shares: Current Nasdaq market coverage.

More news and analyses on Viking Therapeutics stock

Disclaimer...
en | boerse | 70526845 |